Abstract |
CD25 and CD30 represent suitable target molecules for bispecific antibody (bimAb)-driven toxin delivery to lymphoid tumour cells. We describe two new anti-CD30/anti- saporin bimAbs (termed CD30 x sap1 and CD30 x sap2), produced by hybrid hybridomas, which react against non-cross-reactive epitopes of the saporin molecule, and compared their effect with a bimAb reacting with saporin and with CD25 (CD25 x sap1). In a protein synthesis inhibition assay these bimAbs were able to enhance saporin toxicity (IC50 = 8.5 x 10(-9) M in the absence of mAbs) with a similar activity: in the presence of 10(-9) M CD30 x sap1 bimAb the IC50 was 2.75 x 10(-11) M, whereas with CD30 x sap2 bimAb the IC50 was 6.5 x 10(-11) M and CD25 x sap1 bimAb displayed an IC50 of 3 x 10(-11) M (as saporin). The combined use of the two anti-CD30 bimAbs further increased cytotoxicity by 100-fold, resulting in an IC50 of 1.9 x 10(-13) M. A slightly less efficient improvement was obtained by combining the CD25 x sap1 bimAb with the CD30 x sap2 bimAb directed against a different toxin epitope ( saporin IC50 to 7 x 10(-13) M). In contrast, no synergistic effect was observed using the combination of the anti-CD25 bimAb with the anti-CD30 bimAb reacting with the same epitope of saporin (IC50 = 4.5 x 10(-11) M). Analysis of FITC- saporin binding to L540 cells by flow cytometry demonstrated that the appropriate combinations of the two anti-CD30/anti- saporin bimAbs or of the anti-CD30/anti- saporin and anti-CD25/anti- saporin bimAbs had a cooperative effect on the binding of the ribosome-inactivating protein (RIP) to the cells, when compared with single bimAbs.
|
Authors | S Sforzini, D de Totero, A Gaggero, R Ippoliti, M J Glennie, S Canevari, H Stein, S Ferrini |
Journal | British journal of haematology
(Br J Haematol)
Vol. 102
Issue 4
Pg. 1061-8
(Sep 1998)
ISSN: 0007-1048 [Print] England |
PMID | 9734659
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Bispecific
- Antigens, Neoplasm
- Antineoplastic Agents, Phytogenic
- Immunotoxins
- Ki-1 Antigen
- Neoplasm Proteins
- Plant Proteins
- Receptors, Interleukin-2
- Ribosome Inactivating Proteins, Type 1
- N-Glycosyl Hydrolases
- Saporins
|
Topics |
- Antibodies, Bispecific
(biosynthesis, immunology)
- Antigens, Neoplasm
(immunology)
- Antineoplastic Agents, Phytogenic
(immunology, pharmacokinetics, pharmacology)
- Cell Death
(drug effects)
- Dose-Response Relationship, Drug
- Hodgkin Disease
(immunology, metabolism)
- Humans
- Hybridomas
(immunology)
- Immunotoxins
(pharmacokinetics)
- Ki-1 Antigen
(immunology)
- N-Glycosyl Hydrolases
- Neoplasm Proteins
(biosynthesis)
- Plant Proteins
(immunology, pharmacokinetics, pharmacology)
- Receptors, Interleukin-2
(immunology)
- Ribosome Inactivating Proteins, Type 1
- Saporins
- Tumor Cells, Cultured
|